Key Points
- Alkermes SVP Christian Todd Nichols sold 6,000 shares at an average price of $30.00 on March 2 for $180,000, reducing his stake by 5.18% to 109,769 shares (about $3.29M value).
- Alkermes missed quarterly EPS, reporting $0.29 vs. a $0.43 consensus while revenue was $384.6M (slightly above estimates) and the company set FY 2026 guidance of -0.798 to -0.680 EPS.
- The stock recently traded at $28.23 (market cap ~$4.7B) and carries an average analyst rating of “Moderate Buy” with a consensus target of $44.07, though price targets and ratings have varied among analysts.
Alkermes plc (NASDAQ:ALKS - Get Free Report) SVP Christian Todd Nichols sold 6,000 shares of Alkermes stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $30.00, for a total transaction of $180,000.00. Following the completion of the transaction, the senior vice president owned 109,769 shares in the company, valued at approximately $3,293,070. This trade represents a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Alkermes Stock Performance
Alkermes stock traded down $1.06 during trading hours on Thursday, reaching $28.23. 182,879 shares of the stock were exchanged, compared to its average volume of 2,035,937. The stock has a market cap of $4.70 billion, a P/E ratio of 19.77, a P/E/G ratio of 7.28 and a beta of 0.53. Alkermes plc has a 52-week low of $25.17 and a 52-week high of $36.32. The firm's 50 day moving average is $31.60 and its 200 day moving average is $30.24.
Alkermes (NASDAQ:ALKS - Get Free Report) last issued its earnings results on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing the consensus estimate of $0.43 by ($0.14). The firm had revenue of $384.55 million during the quarter, compared to analysts' expectations of $380.44 million. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. The firm's revenue was down 10.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.05 EPS. Alkermes has set its FY 2026 guidance at -0.798--0.680 EPS. Equities research analysts expect that Alkermes plc will post 1.31 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts have recently commented on the company. Royal Bank Of Canada reduced their price target on Alkermes from $47.00 to $45.00 and set an "outperform" rating for the company in a report on Thursday, February 26th. Bank of America increased their price objective on Alkermes from $33.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, February 20th. Zacks Research lowered shares of Alkermes from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 19th. Wells Fargo & Company upped their price target on shares of Alkermes from $37.00 to $43.00 and gave the stock an "overweight" rating in a research note on Thursday, February 26th. Finally, Truist Financial increased their price target on shares of Alkermes from $50.00 to $55.00 and gave the company a "buy" rating in a report on Monday, November 17th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Alkermes presently has an average rating of "Moderate Buy" and a consensus target price of $44.07.
View Our Latest Analysis on Alkermes
Hedge Funds Weigh In On Alkermes
Hedge funds have recently added to or reduced their stakes in the business. Assetmark Inc. raised its position in Alkermes by 933.8% during the third quarter. Assetmark Inc. now owns 827 shares of the company's stock worth $25,000 after acquiring an additional 747 shares during the last quarter. Cullen Frost Bankers Inc. purchased a new position in shares of Alkermes during the 4th quarter worth approximately $28,000. Johnson Financial Group Inc. purchased a new position in shares of Alkermes during the 3rd quarter worth approximately $31,000. UMB Bank n.a. raised its position in shares of Alkermes by 57.6% during the 4th quarter. UMB Bank n.a. now owns 1,220 shares of the company's stock worth $34,000 after purchasing an additional 446 shares during the last quarter. Finally, Hantz Financial Services Inc. lifted its stake in Alkermes by 395.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,239 shares of the company's stock valued at $37,000 after buying an additional 989 shares in the last quarter. 95.21% of the stock is currently owned by hedge funds and other institutional investors.
Alkermes Company Profile
(
Get Free Report)
Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes' portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.
Alkermes' commercial franchise features several approved products.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
